{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:35:51Z","timestamp":1772120151188,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Netw Model Anal Health Inform Bioinforma"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s13721-021-00341-3","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T11:13:27Z","timestamp":1643973207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Screening of potential inhibitors of COVID-19 with repurposing approach via molecular docking"],"prefix":"10.1007","volume":"11","author":[{"given":"Negin","family":"Alizadehmohajer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abtin","family":"Behmardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simin","family":"Najafgholian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shabnam","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Forogh","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9922-7181","authenticated-orcid":false,"given":"Reza","family":"Nedaeinia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaghayegh","family":"Haghjooy Javanmard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehsan","family":"Sohrabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasoul","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon A.","family":"Ferns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asieh","family":"Emami Nejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa","family":"Manian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"key":"341_CR1","doi-asserted-by":"publisher","unstructured":"Arya R, Das A, Prashar V, Kumar M (2020) Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs. ChemRxiv. https:\/\/doi.org\/10.26434\/chemrxiv.11860011.v2","DOI":"10.26434\/chemrxiv.11860011.v2"},{"key":"341_CR3","doi-asserted-by":"publisher","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","volume":"178","author":"L Caly","year":"2020","unstructured":"Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM (2020) The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir Res 178:104787","journal-title":"Antivir Res"},{"issue":"1","key":"341_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","volume":"146","author":"Y Cao","year":"2020","unstructured":"Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L et al (2020) Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol 146(1):137\u201346.e3","journal-title":"J Allergy Clin Immunol"},{"key":"341_CR5","first-page":"E005","volume":"36","author":"C Chen","year":"2020","unstructured":"Chen C, Zhang X, Ju Z, He W (2020) Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies. Chin J Burns 36:E005","journal-title":"Chin J Burns"},{"key":"341_CR6","doi-asserted-by":"crossref","unstructured":"Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y et al (2020) Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv 2020.03.17.20037432","DOI":"10.1101\/2020.03.17.20037432"},{"key":"341_CR7","first-page":"1664","volume":"11","author":"S Choudhary","year":"2020","unstructured":"Choudhary S, Malik YS, Tomar S, Tomar S (2020) Identification of SARS-CoV-2 cell entry inhibitors by drug repurposing using in silico structure-based virtual screening approach. ChemRxiv 11:1664","journal-title":"ChemRxiv"},{"key":"341_CR8","doi-asserted-by":"publisher","unstructured":"Cavasotto C, Filippo JD (2020) In silico Drug Repurposing for COVID-19: Targeting SARS-CoV-2 Proteins through Docking and Quantum Mechanical Scoring. ChemRxiv. https:\/\/doi.org\/10.26434\/chemrxiv.12110199.v2","DOI":"10.26434\/chemrxiv.12110199.v2"},{"issue":"19","key":"341_CR9","doi-asserted-by":"publisher","first-page":"8924","DOI":"10.1128\/JVI.01429-16","volume":"90","author":"CM Coleman","year":"2016","unstructured":"Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frieman MB (2016) Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus fusion. J Virol 90(19):8924\u20138933","journal-title":"J Virol"},{"key":"341_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jpeds.2020.05.007","volume":"223","author":"RL DeBiasi","year":"2020","unstructured":"DeBiasi RL, Song X, Delaney M, Bell M, Smith K, Pershad J et al (2020) Severe COVID-19 in children and young adults in the Washington, DC metropolitan region. J Pediatr 223:199\u2013203","journal-title":"J Pediatr"},{"key":"341_CR11","doi-asserted-by":"publisher","first-page":"102991","DOI":"10.1016\/j.critrevonc.2020.102991","volume":"152","author":"G Di Lorenzo","year":"2020","unstructured":"Di Lorenzo G, Di Trolio R, Kozlakidis Z, Busto G, Ingenito C, Buonerba L et al (2020) COVID 19 therapies and anti-cancer drugs: a systematic review of recent literature. Crit Rev Oncol Hematol 152:102991","journal-title":"Crit Rev Oncol Hematol"},{"key":"341_CR12","doi-asserted-by":"publisher","first-page":"104277","DOI":"10.1016\/j.micpath.2020.104277","volume":"148","author":"M Divya","year":"2020","unstructured":"Divya M, Vijayakumar S, Chen J, Vaseeharan B, Dur\u00e1n-Lara EF (2020) South Indian medicinal plants can combat deadly viruses along with COVID-19? A review. Microb Pathog 148:104277","journal-title":"Microb Pathog"},{"key":"341_CR13","doi-asserted-by":"publisher","unstructured":"Durdagi S, Aksoydan B, Dogan B, et al (2020) Screening of clinically approved and investigation drugs as potential inhibitors of SARS-CoV-2 main protease and spike receptor-binding domain bound with ACE2 COVID19 target proteins: a virtual drug repurposing study. ChemRxiv. https:\/\/doi.org\/10.26434\/chemrxiv.12032712.v2","DOI":"10.26434\/chemrxiv.12032712.v2"},{"issue":"5","key":"341_CR14","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","volume":"6","author":"RT Eastman","year":"2020","unstructured":"Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall MD (2020) Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci 6(5):672\u2013683. https:\/\/doi.org\/10.1021\/acscentsci.0c00489","journal-title":"ACS Cent Sci."},{"key":"341_CR15","doi-asserted-by":"publisher","unstructured":"Elfiky A, Ibrahim NS (2020) Anti-SARS and anti-HCV drugs repurposing against the Papain-like protease of the newly emerged coronavirus (2019-nCoV). Preprint (Version 1). Research Square. https:\/\/doi.org\/10.21203\/rs.2.23280\/v1","DOI":"10.21203\/rs.2.23280\/v1"},{"key":"341_CR16","doi-asserted-by":"crossref","unstructured":"Elfiky AA, Ibrahim NS (2020) Anti-SARS and anti-HCV drugs repurposing against the papain-like protease of the newly emerged coronavirus (2019-nCoV)","DOI":"10.21203\/rs.2.23280\/v1"},{"key":"341_CR17","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S1473-3099(20)30262-0","volume":"20","author":"EG Favalli","year":"2020","unstructured":"Favalli EG, Biggioggero M, Maioli G, Caporali R (2020) Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis 20:1012\u20131013","journal-title":"Lancet Infect Dis"},{"key":"341_CR18","first-page":"013056","volume":"jbc.AC120","author":"CJ Gordon","year":"2020","unstructured":"Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Gotte M (2020) The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem jbc.AC120:013056","journal-title":"J Biol Chem"},{"key":"341_CR19","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","volume":"382","author":"J Grein","year":"2020","unstructured":"Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A et al (2020) Compassionate use of remdesivir for patients with severe covid-19. N Engl J Med 382:2327\u20132336","journal-title":"N Engl J Med"},{"issue":"5","key":"341_CR20","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jinf.2020.02.026","volume":"80","author":"IM Ibrahim","year":"2020","unstructured":"Ibrahim IM, Abdelmalek DH, Elshahat ME, Elfiky AA (2020) COVID-19 spike-host cell receptor GRP78 binding site prediction. J Infect 80(5):554\u2013562","journal-title":"J Infect"},{"issue":"5","key":"341_CR21","doi-asserted-by":"publisher","first-page":"L1025","DOI":"10.1152\/ajplung.00119.2020","volume":"318","author":"H Jakovac","year":"2020","unstructured":"Jakovac H (2020) COVID-19: is the ACE2 just a foe? Am J Physiol Lung Cell Mol Physiol 318(5):L1025\u2013L1026","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"8","key":"341_CR22","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nm1446","volume":"12","author":"R Kerkel\u00e4","year":"2006","unstructured":"Kerkel\u00e4 R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12(8):908\u2013916","journal-title":"Nat Med"},{"issue":"1","key":"341_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1242\/jcs.175521","volume":"129","author":"A Khatri","year":"2016","unstructured":"Khatri A, Wang J, Pendergast AM (2016) Multifunctional Abl kinases in health and disease. J Cell Sci 129(1):9","journal-title":"J Cell Sci"},{"issue":"1\u20132","key":"341_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/0014-5793(89)80886-5","volume":"252","author":"EV Koonin","year":"1989","unstructured":"Koonin EV, Gorbalenya AE, Chumakov KM (1989) Tentative identification of RNA-dependent RNA polymerases of dsRNA viruses and their relationship to positive strand RNA viral polymerases. FEBS Lett 252(1\u20132):42\u201346","journal-title":"FEBS Lett"},{"issue":"2","key":"341_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nrd3652","volume":"11","author":"RA Mesa","year":"2012","unstructured":"Mesa RA, Yasothan U, Kirkpatrick P (2012) Ruxolitinib. Nat Rev Drug Discov 11(2):103\u2013104","journal-title":"Nat Rev Drug Discov"},{"key":"341_CR26","doi-asserted-by":"crossref","unstructured":"Mulgaonkar N, Wang H, Mallawarachchi S, Fernando S, Martina B, Ruzek D (2020) Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19. bioRxiv 2020.06.18.158196","DOI":"10.1101\/2020.06.18.158196"},{"key":"341_CR28","doi-asserted-by":"publisher","unstructured":"Pal R, Bhadada SK (2020) Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes Res Clin Pract. 163:108146. https:\/\/doi.org\/10.1016\/j.diabres.2020.108146.","DOI":"10.1016\/j.diabres.2020.108146"},{"issue":"1","key":"341_CR29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1600-065X.2008.00644.x","volume":"223","author":"M Pesu","year":"2008","unstructured":"Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O\u2019Shea JJ (2008) Therapeutic targeting of Janus kinases. Immunol Rev 223(1):132\u2013142","journal-title":"Immunol Rev"},{"issue":"1","key":"341_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12932\/ap-200220-0772","volume":"38","author":"E Prompetchara","year":"2020","unstructured":"Prompetchara E, Ketloy C, Palaga T (2020) Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 38(1):1\u20139. https:\/\/doi.org\/10.12932\/ap-200220-0772.","journal-title":"Asian Pacific journal of allergy and immunology."},{"key":"341_CR31","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/cid\/ciaa248","volume":"71","author":"C Qin","year":"2020","unstructured":"Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y et al (2020) Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 71:762\u2013768","journal-title":"Clin Infect Dis"},{"issue":"3","key":"341_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jbspin.2020.03.011","volume":"87","author":"L Quartuccio","year":"2020","unstructured":"Quartuccio L, Semerano L, Benucci M, Boissier M-C, De Vita S (2020) Urgent avenues in the treatment of COVID-19: targeting downstream inflammation to prevent catastrophic syndrome. Jt Bone Spine 87(3):191","journal-title":"Jt Bone Spine"},{"key":"341_CR33","unstructured":"Riviere P, Riviere M, Reader S (2012) Use of imatinib to treat liver disorders and viral infections. Google Patents"},{"issue":"5","key":"341_CR34","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1161\/ATVBAHA.115.305085","volume":"35","author":"AN Rizzo","year":"2015","unstructured":"Rizzo AN, Aman J, van Nieuw Amerongen GP, Dudek SM (2015) Targeting Abl kinases to regulate vascular leak during sepsis and acute respiratory distress syndrome. Arterioscler Thromb Vasc Biol 35(5):1071\u20131079","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"341_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/14728214.2019.1591369","volume":"24","author":"TD Shaw","year":"2019","unstructured":"Shaw TD, McAuley DF, O\u2019Kane CM (2019) Emerging drugs for treating the acute respiratory distress syndrome. Expert Opin Emerg Drugs 24(1):29\u201341","journal-title":"Expert Opin Emerg Drugs"},{"issue":"5","key":"341_CR36","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1099\/jgv.0.001047","volume":"99","author":"JM Sisk","year":"2018","unstructured":"Sisk JM, Frieman MB, Machamer CE (2018) Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. J Gen Virol 99(5):619","journal-title":"J Gen Virol"},{"key":"341_CR37","first-page":"E014","volume":"43","author":"M Sun","year":"2020","unstructured":"Sun M, Yang J, Sun Y, Su G (2020) Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia. Chin J Tuberc Respir Dis 43:E014","journal-title":"Chin J Tuberc Respir Dis"},{"key":"341_CR38","doi-asserted-by":"publisher","unstructured":"Talluri S (2020) Molecular Docking and Virtual Screening based prediction of drugs for COVID-19. Comb Chem High Throughput Screen 23:1. https:\/\/doi.org\/10.2174\/1386207323666200814132149","DOI":"10.2174\/1386207323666200814132149"},{"issue":"7","key":"341_CR39","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/cid\/ciaa879","volume":"72","author":"BK Titanji","year":"2021","unstructured":"Titanji BK, Farley MM, Mehta A, Connor-Schuler R, Moanna A, Cribbs SK, O'Shea J, DeSilva K, Chan B, Edwards A, Gavegnano C, Schinazi RF, Marconi VC (2021) Use of baricitinib in patients with moderate to severe coronavirus disease 2019. Clin Infect Dis 72(7):1247\u20131250. https:\/\/doi.org\/10.1093\/cid\/ciaa879","journal-title":"Clin Infect Dis"},{"key":"341_CR40","unstructured":"Tools A (2016) 1.5. 6 (ADT)\/MGL Tools 1.5. 6, The Scripps Research Institute, CA, USA, 2012"},{"issue":"2","key":"341_CR41","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455\u2013461","journal-title":"J Comput Chem"},{"issue":"3","key":"341_CR42","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M et al (2020a) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30(3):269\u2013271","journal-title":"Cell Res"},{"key":"341_CR43","doi-asserted-by":"publisher","unstructured":"Wang D, Guo J, Yang Z, You Y, Chen Z, Chen S, et al (2020 )The first report of the prevalence of COVID-19 in Chronic myelogenous leukemia patients in the core epidemic area of China: multicentre, cross-sectional survey. medRxiv. https:\/\/doi.org\/10.1101\/2020.03.12.20034876","DOI":"10.1101\/2020.03.12.20034876"},{"key":"341_CR27","unstructured":"World Health Organization (WHO) (2020) Coronavirus disease 2019 (COVID-19) situation report-45. https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/situation-reports\/20200305-sitrep-45-covid-19.pdf"},{"issue":"SI-1","key":"341_CR44","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3906\/sag-2004-145","volume":"50","author":"S Yavuz","year":"2020","unstructured":"Yavuz S, \u00dcnal S (2020) Antiviral treatment of COVID-19. Turk J Med Sci 50(SI-1):611\u2013619","journal-title":"Turk J Med Sci"},{"key":"341_CR45","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","volume":"17","author":"M Zheng","year":"2020","unstructured":"Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D et al (2020) Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 17:533\u2013535","journal-title":"Cell Mol Immunol"},{"issue":"7798","key":"341_CR46","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798):270\u2013273","journal-title":"Nature"}],"container-title":["Network Modeling Analysis in Health Informatics and Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13721-021-00341-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13721-021-00341-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13721-021-00341-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T18:39:28Z","timestamp":1700159968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13721-021-00341-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["341"],"URL":"https:\/\/doi.org\/10.1007\/s13721-021-00341-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-94371\/v1","asserted-by":"object"}]},"ISSN":["2192-6662","2192-6670"],"issn-type":[{"value":"2192-6662","type":"print"},{"value":"2192-6670","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,4]]},"assertion":[{"value":"24 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"11"}}